Announcement • Mar 13
Nasdaq to Delist the Ordinary Shares Class A, Unit, Warrant of APx Acquisition Corp I Nasdaq announced that it will delist the ordinary shares Class A, unit, warrant of APx Acquisition Corp. I. APx Acquisition Corp.’s stock was suspended on December 17, 2024 and has not traded on Nasdaq since that time. Announcement • Dec 18
Nasdaq Determines to Delist APx Acquisition Corp. I Securities On December 10, 2024, APX Acquisition Corp. I (the Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (Nasdaq") stating that, pursuant to Nasdaq Listing Rule IM-5101-2 (Rule IM-5101-2"), the staff of Nasdaq (Staff") had determined that (i) the Company's securities will be delisted from Nasdaq, (ii) trading of the Company's Class A common stock, warrants, and units will be suspended at the opening of business on December 17, 2024 and (iii) a Form 25-NSE will be filed with the Securities and Exchange Commission (the SEC"), which will remove the Company's securities from listing and registration on Nasdaq. Under Rule IM-5101-2, a special purpose acquisition company must complete one or more business combinations within 36 months of the effectiveness of its initial public offering registration statement. Since the Company failed to complete its initial business combination by December 6, 2024, the Staff concluded that the Company did not comply with Rule IM-5101-2 and that the Company's securities are now subject to delisting. The Company intends to apply for the listing of its securities on the OTC market after they are delisted from Nasdaq. The delisting from Nasdaq and the commencement of trading on the OTC market does not affect the Company's previously announced business combination with OmnigenicsAI Corp, a Cayman Islands exempted company (Omnigenics"), as both parties continue to work to effectuate the closing of the business combination. Omnigenics will apply for listing of its securities on the Nasdaq Stock Market in connection with the closing of the business combination. The Company will remain a reporting entity under the Securities Exchange Act of 1934, as amended, with respect to continued disclosure of financial and operational information. Announcement • Nov 03
APX Acquisition Announces Nasdaq Delisting Notification for Units As previously announced, on September 4, 2024, APX Acquisition Corp. I (the ‘Company’), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market (‘Nasdaq’) indicating that since the Company's aggregate market value of its outstanding warrants was less than $1 million, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set in Listing Rule 5452(b)(C) (the ‘Rule’), which requires the Company to maintain an aggregate market value of its outstanding warrants of at least $1 million (the ‘Notice’). The Company subsequently submitted a plan to regain compliance with the Rule (the ‘Compliance Plan’).On October 29, 2024, the Company received written notice from the Staff (the ‘November Notice’), stating that the Compliance Plan was not accepted as the Company had provided insufficient evidence to demonstrate that it can effect the Compliance Plan by its 36-month expiration date of December 6, 2024, at which time the Company's securities will be delisted from Nasdaq in accordance with IM-5101-2, irrespective of the Company's progress or lack thereof toward regaining compliance with the Rule, and that the Staff had determined to initiate procedures to delist the Company's warrants (and, as a result of the warrants' inclusion therein, the Company's units) from Nasdaq due to the Company's non-compliance. Pursuant to the Notice, unless the Company requests a hearing to appeal this determination by November 5, 2024, the Company's warrants and units will be suspended at the opening of business on November 5, 2024, and a Form 25-NSE will be filed with the SEC, which will remove the Company's warrants and units from listing and registration on Nasdaq (the ‘Warrant/Unit Delisting’). The Company does not intend to request a hearing. The Warrant/Unit Delisting does not affect the listing or trading of the Company's Class A ordinary shares on the Nasdaq Global Market, other than those contained within the units. Announcement • Jun 06
APx Acquisition Corp. I Receives Written Notice from Nasdaq Regarding Non-Compliance with the Nasdaq Listing Rule 5250(c)(1) On May 30, 2024, APx Acquisition Corp. I (the ‘Company’), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market (‘Nasdaq’) indicating that since the Company had not yet filed its Form 10-K for the period ended December 31, 2023 nor had it filed its Form 10-Q for the period ended March 31, 2024, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set forth in Listing Rule 5250(c)(1) (the ‘Rule’), which requires the Company to timely file all required periodic financial reports with the Securities and Exchange Commission through the EDGAR System (the ‘Notice’). The Notice additionally indicates that the Company, pursuant to the Listing Rules, has 60 calendar days, to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, the Company will have 180 calendar days from the referenced Form 10-K’s due date, or until September 27, 2024, to evidence compliance. If Nasdaq were to reject the Company’s plan, Nasdaq rules permit the Company to appeal the decision to a hearings panel. The Notice serves only as a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the Nasdaq Global Market. The Company intends to take action to submit a plan to regain compliance within the 60 calendar days submission period, and, if Nasdaq accepts the plan to regain compliance, to subsequently regain compliance with the Rule within the 180 calendar day compliance period. While the Company is exercising diligent efforts to maintain the listing of its securities on Nasdaq Global Market, there can be no assurance that the Company will be able to regain or maintain compliance with the Rule. In addition, if the Company does not meet the Rule’s requirement by the end of the 180 calendar day compliance period, Nasdaq could provide notice that the Company’s securities will become subject to delisting. In the event the Company receives notice that its securities are being delisted, Nasdaq rules permit the Company to appeal any delisting determination by the Nasdaq staff to a hearings panel. Announcement • Mar 27
OmnigenicsAI Corp entered into a definitive Business Combination Agreement to acquire APx Acquisition Corp. I (NasdaqGM:APXI). OmnigenicsAI Corp entered into a definitive Business Combination Agreement to acquire APx Acquisition Corp. I (NasdaqGM:APXI) on March 26, 2023. Pursuant to the BCA: (i) APx will merge with OmnigenicsAI, with APx being the surviving entity and becoming a wholly owned subsidiary of OmnigenicsAI and (ii) APx’s ordinary shares and warrants will be exchanged for ordinary shares and warrants of OmnigenicsAI. Upon closing, OmnigenicsAI shares and warrants are expected to be publicly listed on Nasdaq under the ticker symbols “OMNI” and “OMNIW”, respectively. The transaction is subject to the approval of APx’s shareholders. The transaction is expected to close mid-year, 2024. Greenberg Traurig, LLP, Maples & Calder (Cayman) LLP and Pérez Alati, Grondona, Benites & Arntsen acted as U.S./U.K., Cayman and Argentine legal counsel, respectively, to APx. EarlyBirdCapital, Inc. acted as M&A advisor to APx. Linklaters LLP, Ogier and Marval, O'Farrell & Mairal acted as U.S., Cayman and Argentine legal counsel, respectively, to OmnigenicsAI. Board Change • Mar 19
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Director Daniel Mudd was the last director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 
